Latest News

December 13, 2017

Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment. Read more

November 6, 2017

Pionyr Immunotherapeutics Appears in BioCentury. View article

January 4, 2017

Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics. Read more